论文部分内容阅读
目的验证氢化麦角碱（ＤＥＴ）治疗急性缺血性脑血管病的临床疗效及安全性。方法设立ＤＥＴ治疗组和低分子右旋糖酐对照组，治疗前后采用神经功能缺损和生活能力状态量表评分，再进行临床疗效判定。结果ＤＥＴ组治疗后神经功能缺损评分显著减少（Ｐ＜０．０１），病残程度显著改善（Ｐ＜０．０１），治疗显效率６７％，高于低分子右旋糖酐治疗组４０％（Ｐ＜０．０５）。结论ＤＥＴ对急性缺血性脑血管病有较好疗效，副作用少而轻。
Objective To verify the clinical efficacy and safety of hydrogenated ergotine (DET) in the treatment of acute ischemic cerebrovascular disease. Methods The DET group and low molecular dextran control group were established. The neurological impairment and viability status scale were used before and after treatment, and then the clinical efficacy was determined. Results After treatment, the scores of neurological deficit in DET group decreased significantly (P <0.01), and the degree of sick and disabled significantly improved (P <0.01), the effective rate of treatment was 67%, which was higher than that of low molecular dextran treatment group (P < 0.05). Conclusion DET has good curative effect on acute ischemic cerebrovascular disease with few side effects.